Comparitive study on effect of combination of metformin-vildagliptin vs metformin-glimepride on lipid profile in patients of type 2 diabetes mellitus

Background: The global burden of Type 2 diabetes mellitus (T2DM) is on a rise.It is an endrocrine disorder characterised by hyperglycaemia. Cardiac morbidity in patients of long standing type 2 diabetes mellitus is said to occur due to dyslipidaemia seconadary to hyperglycaemia. Good glycaemic control may prevent such a mobidity to occur by intake of efficacious antidiabetic drugs either alone or in combination. Thus, our aim was to analyse the effect of metformin-vildagliptin vs metformin-glimepride on lipid profile of patients of type 2 diabetes mellitus. Methods: Our study was an observational comparative study where 200 patients of type 2 diabetes mellitus attending medicine department OPD at Shri Shankaracharya Institute of Medical Sciences (SSIMS), Bhillai were included. They were divided in two equal groups of 100 each, where group A were using Metformin-vildagliptin combination, whereas Group B were using Metformin- glimepride combination. All blood investigations were done to decipher glycaemic control and lipid profile status. The results of the two groups were compared and statiscally analysed. Results: Better glycaemic control was seen in patients of group A as compared to those in Group B after treatment, which was statistically significant. A reduction in triglyceride (TGL), low density lipoprotein (LDL) levels and improvement in high density lipoprotein (HDL) levels was seen in patients of Group Aas compared to those in Group B, which was statistically significant. Conclusions: Patients on combination of met formin-vildagliptin (Group A) had greater reduction in lipid profile parameters as compared to metformin- glimepride (Group B).